Eva Bredberg
Experimental Medicine
AstraZeneca R&D
Mölndal
Sweden
Name/email consistency: high
- Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Bredberg, E., Andersson, T.B., Frison, L., Thuresson, A., Johansson, S., Eriksson-Lepkowska, M., Larsson, M., Eriksson, U.G. Clin. Pharmacokinet (2003)